Feasibility of a Sensor-less Sleep Monitor (Somnofy®) in Diagnosis and Follow-up in Obstructive Sleep Apnea.
Long Distance Diagnostics of Sleep Apnea With Objective Sleep Data From a Sensor-less Monitor - a Feasibility Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Hanne Sorger, md phd
- Phone Number: +4791816787
- Email: hanne.sorger@ntnu.no
Study Contact Backup
- Name: Vigdis Fossland
- Phone Number: +74098361
- Email: vigdis.fossland@hnt.no
Study Locations
-
-
-
Levanger, Norway
- Department of Pulmonology, Levanger Hospital, North Trøndelag Hospital Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- referred to the pulmonology department in the participating hospital (Sykehuset Levanger) with suspected sleep apnea
- able to sign an informed consent
Exclusion Criteria:
- Pregnancy
- Serious disease which could affect ability to complete the study
- Complicated sleep disorders
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Sleep apnea group
Patients with undiagnosed suspected sleep apnea who are referred to Levanger Hospital for respiratory polygraphy
|
Registration of sleep score and apneas with radar sensor technology at time of primary investigation and 12 weeks after treatment initiation with continuous positive airway pressure (CPAP)
Other Names:
|
|
Control group
partners of patients with undiagnosed suspected sleep apnea who are referred to Levanger Hospital for respiratory polygraphy
|
Registration of sleep score and apneas with radar sensor technology at time of primary investigation and 12 weeks after treatment initiation with continuous positive airway pressure (CPAP)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Apnea/hypopnea index
Time Frame: 72 hours
|
Apnea/hypopnea index defined as the number of apneas or hypopneas per hours of sleep
|
72 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sleep score
Time Frame: 12 weeks
|
Objective (AI-based) score of sleep quality from raw data from sleep monitor
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Øystein Risa, phd, NTNU, Fac of Med and Health Sci, Dept of Circulation and Medical Imaging
- Study Director: Carl Platou, MD, North Trøndelag Hospital Trust
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 200405
- CIV-NO-21-08-037486 (Other Identifier: Eudamed)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.